Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-03 | 2024-03 | -0.22 | N/A | N/A | N/A |
2024-03-08 | 2023-12 | -0.17 | -0.22 | -0.05 | -29.41% |
2023-11-03 | 2023-09 | -0.18 | -0.16 | 0.02 | 11.11% |
2023-08-04 | 2023-06 | -0.21 | -0.18 | 0.03 | 14.29% |
2023-05-05 | 2023-03 | -0.18 | -0.19 | -0.01 | -5.56% |
2023-03-13 | 2022-12 | -0.19 | -0.16 | 0.03 | 15.79% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-06-13 | JonesTrading | Upgrade | Buy | |
2023-05-01 | Ladenburg Thalmann | Upgrade | Buy | |
2022-08-28 | Citigroup | Upgrade | Neutral | |
2022-05-19 | Citigroup | Upgrade | Neutral | |
2021-08-24 | Citigroup | Upgrade | Neutral | |
2021-04-19 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2019-02-25 | BERNSTEIN KAREN | Director | 20.00K | Purchase |
2017-05-09 | DURING MATTHEW M.D. | President | 4.68M | Conversion of Exercise of derivative security |
2024-03-17 | LEVIN JEREMY M | Chief Executive Officer | 3.65M | Purchase |
2024-02-21 | PERONE THOMAS MICHAEL | General Counsel | 28.13K | Stock Award(Grant) |
2021-07-13 | RAKHIT AMIT M.D. | President | 726.82K | Sale |
2024-02-21 | RONA JEFFREY A | Chief Financial Officer | 28.13K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | BVF Inc. | 6.85M | 22.47M | 9.70% |
2023-06-29 | EcoR1 Capital, LLC | 6.12M | 20.07M | 8.66% |
2023-06-29 | Rubric Capital Management LP | 5.45M | 17.86M | 7.71% |
2023-06-29 | Blackrock Inc. | 3.41M | 11.18M | 4.83% |
2023-06-29 | Madison Avenue Partners, LP | 3.31M | 10.85M | 4.68% |
2023-06-29 | Vanguard Group Inc | 2.90M | 9.51M | 4.11% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.85M | 6.07M | 2.62% |
2023-08-30 | iShares Russell 2000 ETF | 1.20M | 4.04M | 1.70% |
2023-06-29 | Vanguard Extended Market Index Fund | 695.68K | 2.28M | 0.99% |
2023-07-30 | Fidelity Small Cap Index Fund | 519.63K | 1.87M | 0.74% |
2023-08-30 | iShares Russell 2000 Value ETF | 498.03K | 1.68M | 0.71% |
2023-05-30 | Fidelity Extended Market Index Fund | 271.23K | 960.16K | 0.38% |
-
-
$OBSV
Don’t mis this run. Lots of upside potential.ObsEva SA (NASDAQ:OBSV) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
-
$OBSV
Don’t mis this run. Lots of upside potential.ObsEva SA (NASDAQ:OBSV) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
-
-
-
-
-
-
-
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
globenewswire.com • -
3 Very Promising Penny Stocks That Are Flying Under the Radar
investorplace.com • -
3 Biotech Stocks Under $10 to Add to Your Buy List
investorplace.com • -
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
globenewswire.com • -
Ovid Therapeutics: Good Entry Point For Investors
seekingalpha.com • -
HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover
investorplace.com • -
8 Biotech Penny Stocks for Investors to Watch
investorplace.com • -
OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocketing Higher Today
investorplace.com • -
Why Ovid, KemPharm, Sorrento, Aquestive Are Rallying
benzinga.com • -
Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
globenewswire.com • -
Altimmune COVID Update, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com • -
Novavax和武田宣布在日本合作Novavax的COVID-19候选疫苗
businesswire.com • -
武田宣佈2020會計年度第一季業績;確認管理層指引,並提高全年列報營業利潤和列報淨利潤
businesswire.com • -
Ovid Therapeutics: A Full Investment Analysis
seekingalpha.com • -
3 Top Biotech Stocks to Buy Now
finance.yahoo.com • -
Ovid Therapeutics (NASDAQ:OVID) Rating Reiterated by William Blair
thelincolnianonline.com • -
Ovid Therapeutics (NASDAQ:OVID) PT Raised to $9.00
thelincolnianonline.com • -
Two Sigma Advisers LP Purchases 4,200 Shares of Ovid Therapeutics Inc (NASDAQ:OVID)
thelincolnianonline.com • -
Ovid Therapeutics (NASDAQ:OVID) Shares Up 5.6% After Analyst Upgrade
thelincolnianonline.com • -
Is Ovid Therapeutics Stock a Buy?
finance.yahoo.com • -
Takeda Pharmaceutical Co Ltd (NYSE:TAK) Shares Acquired by Guggenheim Capital LLC
thelincolnianonline.com • -
How Much Of Ovid Therapeutics Inc. (NASDAQ:OVID) Do Insiders Own?
finance.yahoo.com • -
Is Ovid Therapeutics Inc. (OVID) Going to Burn These Hedge Funds?
finance.yahoo.com • -
IPO Update: Nkarta Proposes Terms For $150 Million IPO (Pending:NKTX)
seekingalpha.com • -
Biotech firm Carmine Therapeutics inks US$900m deal with Takeda Pharmaceuticals
businesstimes.com.sg • -
Local gene therapy firm inks $1.2b deal with pharma giant
straitstimes.com • -
Ovid Therapeutics Added to Russell 2000® and Russell 3000® Indexes
finance.yahoo.com • -
Voloridge Investment Management LLC Decreases Stake in Takeda Pharmaceutical Co Ltd (NYSE:TAK)
thelincolnianonline.com • -
Takeda India donates Rs 1.2 cr to PM CARES Fund
devdiscourse.com • -
Okta, CrowdStrike, Netskope, and Proofpoint Join Together to Secure Remote Work | | IT Business Net
business.itbusinessnet.com • -
5 of the Best Pharmaceutical Stocks to Buy Right Now
investorplace.com • -
Ovid Therapeutics (OVID) Jumps: Stock Rises 12.4%
finance.yahoo.com • -
Enterome Closes €46.3M Financing Round | FinSMEs
finsmes.com • -
6 Stocks That Could Edge Higher
investing.com • -
Head to Head Analysis: Ovid Therapeutics (NASDAQ:OVID) & Cotinga Pharmaceuticals (NASDAQ:COTQF)
thelincolnianonline.com • -
Implied Volatility Surging for Ovid Therapeutics (OVID) Stock Options
finance.yahoo.com • -
Ovid Therapeutics (NASDAQ:OVID) Shares Gap Up After Analyst Upgrade
thelincolnianonline.com •